Marc Lang
YOU?
Author Swipe
View article: Supplementary Tables 1-4 from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases
Supplementary Tables 1-4 from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases Open
Suppl. Table 1. Binding mode of Debio 0617B to ABL. Suppl. Table 2. Physico-chemical and early ADME profile of Debio 0617B. Suppl. Table 3. Debio 0617B activity on a panel of 21 cancer cell lines. Suppl. Table 4. PK/PD Profile of Debio 061…
View article: Supplementary Figures legend from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases
Supplementary Figures legend from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases Open
Legend for Supplementary Figures:1A,1B,1C,1D 2A,2B,2C;3A,3B
View article: Supplementary Tables 1-4 from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases
Supplementary Tables 1-4 from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases Open
Suppl. Table 1. Binding mode of Debio 0617B to ABL. Suppl. Table 2. Physico-chemical and early ADME profile of Debio 0617B. Suppl. Table 3. Debio 0617B activity on a panel of 21 cancer cell lines. Suppl. Table 4. PK/PD Profile of Debio 061…
View article: Supplementary Figures 1-3 from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases
Supplementary Figures 1-3 from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases Open
Suppl. Fig. 1 Characterization for pSTAT3 activation in cancer cell lines responding to Debio 0617B in vitro by Western blot analysis.Suppl. Fig. 2 A-C. Efficacy studies with Debio 0617B in A549, A2058 and A431 models: body weight loss/gai…
View article: Supplementary Tables legend from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases
Supplementary Tables legend from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases Open
Legend for Supplementary Tables:1,2,3,4
View article: Supplementary Figures 1-3 from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases
Supplementary Figures 1-3 from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases Open
Suppl. Fig. 1 Characterization for pSTAT3 activation in cancer cell lines responding to Debio 0617B in vitro by Western blot analysis.Suppl. Fig. 2 A-C. Efficacy studies with Debio 0617B in A549, A2058 and A431 models: body weight loss/gai…
View article: Supplementary Tables legend from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases
Supplementary Tables legend from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases Open
Legend for Supplementary Tables:1,2,3,4
View article: Data from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases
Data from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases Open
Tumor survival, metastases, chemoresistance, and escape from immune responses have been associated with inappropriate activation of STAT3 and/or STAT5 in various cancers, including solid tumors. Debio 0617B has been developed as a first-in…
View article: Supplementary Figures legend from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases
Supplementary Figures legend from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases Open
Legend for Supplementary Figures:1A,1B,1C,1D 2A,2B,2C;3A,3B
View article: Data from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases
Data from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases Open
Tumor survival, metastases, chemoresistance, and escape from immune responses have been associated with inappropriate activation of STAT3 and/or STAT5 in various cancers, including solid tumors. Debio 0617B has been developed as a first-in…
View article: Data from Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805
Data from Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805 Open
The recent discovery of an acquired activating point mutation in JAK2, substituting valine at amino acid position 617 for phenylalanine, has greatly improved our understanding of the molecular mechanism underlying chronic myeloproliferativ…
View article: Supplementary Data from Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805
Supplementary Data from Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805 Open
Supplementary Data from Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805
View article: Data from Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805
Data from Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805 Open
The recent discovery of an acquired activating point mutation in JAK2, substituting valine at amino acid position 617 for phenylalanine, has greatly improved our understanding of the molecular mechanism underlying chronic myeloproliferativ…
View article: Supplementary Data from Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805
Supplementary Data from Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805 Open
Supplementary Data from Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805
View article: CARHAB - Q2. Synthèse sur les actions 2017-2018 dans le cadre de l’appui méthodologique à la cartographie des végétations naturelles et semi-naturelles des milieux ouverts de basse altitude
CARHAB - Q2. Synthèse sur les actions 2017-2018 dans le cadre de l’appui méthodologique à la cartographie des végétations naturelles et semi-naturelles des milieux ouverts de basse altitude Open
View article: Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases
Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases Open
Tumor survival, metastases, chemoresistance, and escape from immune responses have been associated with inappropriate activation of STAT3 and/or STAT5 in various cancers, including solid tumors. Debio 0617B has been developed as a first-in…